Drugs / Ex-vivo expanded γδ T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04764513 | Sep 2021 → Apr 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ex-vivo expanded γδ T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04764513 ↗ |
| Modality | Cell therapy | “γδ T cell will be separated from peripheral blood of the same donors. After expansion in vitro, they will be infused to the patients as an immunotherapy treatment.” NCT04764513 ↗ |